Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Short Bowel Syndrome

In brief

The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data. Glepaglutide is the International Nonproprietary Name and United States Adopted Name (USAN) for ZP1848.

Key facts

Study ID
NCT07197944
Run by
Zealand Pharma
People needed
90
Starts
2026-02-11
Expected to finish
2032-02-28
Last updated by the study team
2026-04-20

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.